Holen Sie sich die Stockscreener-App
12.78
0.70%
-0.09
Handel nachbörslich:
12.94
0.16
+1.25%
Day One Biopharmaceuticals Inc Aktie (DAWN) Neueste Nachrichten
Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth - Seeking Alpha
Why Day One Biopharmaceuticals (DAWN) Is Up 17.7% After Positive EU Opinion For OJEMDA Approval - simplywall.st
DAWN Shares Rally On Buyout Speculation But Retail Warns A Deal Might Not Materialise - Stocktwits
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 26.2%What's Next? - MarketBeat
Day One Biopharmaceuticals, Inc. (DAWN) Competitors - Meyka
DAWN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Day One Highlights OJEMDA’s EMA Progress, Updates Strategy - TipRanks
Day One Biopharmaceuticals updates presentation after CHMP positive opinion for OJEMDA; 2026 revenue guidance $225–250M - TradingView
Surging OJEMDA sales and EU backing drive Day One (Nasdaq: DAWN) outlook - Stock Titan
Day One Weighs OJEMDA Momentum Against Expanded Oncology Pipeline Risks - Sahm
DAWN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead (NASDAQ:DAWN) - Seeking Alpha
Research Analysts Issue Forecasts for DAWN Q1 Earnings - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Lowered to Hold at Zacks Research - MarketBeat
Day One Biopharmaceuticals, Inc. (DAWN) Stock Analysis: Exploring 113.62% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Day One Biopharmaceuticals (DAWN) Touts Narrower Q4 Loss Challenging Bearish Profitability Narratives - simplywall.st
Day One Biopharmaceuticals Reports Strong 2025 Financial Results and Growth Outlook - Intellectia AI
Day One Biopharmaceuticals (NASDAQ:DAWN) Announces Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
What Analysts Are Saying About Day One Biopharmaceutical Stock - Benzinga
Needham lowers Day One Biopharmaceuticals price target on costs - Investing.com Australia
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down After Earnings Miss - MarketBeat
Day One Q4 Net Loss Narrows As OJEMDA Sales Jump 82%; Reaffirms FY26 Guidance; Stock Down - Nasdaq
Wedbush Forecasts Strong Price Appreciation for Day One Biopharmaceuticals (NASDAQ:DAWN) Stock - MarketBeat
Needham & Company LLC Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $17.00 - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Lowered to $22.00 at HC Wainwright - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright lowers Day One Biopharmaceuticals price target to $22 By Investing.com - Investing.com Australia
Day One Biopharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:DAWN) 2026-02-25 - Seeking Alpha
Day One Biopharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Day One Biopharmaceuticals earnings missed by $0.02, revenue topped estimates - Investing.com Australia
Day One Biopharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN) and Xenon (XENE) - The Globe and Mail
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue Estimates - Bitget
Day One Biopharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Day One Biopharmaceuticals Q4 Loss Narrows, Revenue Rises; Shares Drop After Hours - marketscreener.com
Day One Highlights Transformational 2025 and OJEMDA Growth - TipRanks
Day One Biopharmaceuticals beats revenue estimates By Investing.com - Investing.com South Africa
Day One Biopharmaceuticals beats revenue estimates - Investing.com
Day One Bio (DAWN) Q4 2025 Earnings Transcript - The Globe and Mail
First Solar Q4 net sales reach $1.68 billion, analysts expected $1.56 billion - Bitget
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance - Bitget
Lucid Group's Q4 revenue was $522.7 million, exceeding analysts' expectations of $459.4 million. - Bitget
Day One Biopharma (NASDAQ: DAWN) grows OJEMDA franchise and ADC oncology pipeline - Stock Titan
Earnings Flash (DAWN) Day One Biopharmaceuticals, Inc. Reports Q4 Revenue $52.8M, vs. FactSet Est of $49.8M - marketscreener.com
Day One Reports Fourth Quarter and Full Year 2025 Financial - GlobeNewswire
First Week of October 16th Options Trading For Day One Biopharmaceuticals (DAWN) - Nasdaq
Day One Biopharmaceuticals earnings up next after Mersana deal - Investing.com South Africa
Day One Biopharmaceuticals earnings up next after Mersana deal By Investing.com - Investing.com Australia
Day One Biopharmaceuticals Inc. (Day One) has officially disclosed its financial report for the fourth quarter and full year of fiscal 2025. - Bitget
Why (DAWN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Examining the Future: Day One Biopharmaceutical's Earnings Outlook - Benzinga
Earnings To Watch: Day One Biopharmaceuticals Inc (DAWN) Reports Q4 2025 Result - GuruFocus
Day One Biopharmaceuticals, Inc. $DAWN Shares Sold by NEOS Investment Management LLC - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Day One Biopharmaceuticals Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
What’s the fair value of Day One Biopharmaceuticals Inc. stockWeekly Trend Recap & Community Consensus Picks - mfd.ru
Day one Biopharma CCO sold $67k in DAWN stock By Investing.com - Investing.com UK
Michael Vasconcelles Sells 2,728 Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) Stock - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Insider Sells $74,182.00 in Stock - MarketBeat
Jeremy Bender Sells 15,459 Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) Stock - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Insider Lauren Merendino Sells 5,814 Shares - MarketBeat
Day one Biopharma CCO sold $67k in DAWN stock - Investing.com UK
Day One Biopharma (DAWN) insider sells shares to cover RSU taxes - Stock Titan
Will Day One Biopharmaceuticals, Inc. (DAWN) report negative earnings next week? What you should know - MSN
Will Day One Biopharmaceuticals, Inc. (DAWN) Report Negative Earnings Next Week? What You Should Know - Finviz
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):